In short
Bloomberg Intelligence Podcast Episode Summary
Episode Title
Meta to Spend Tens of Billions of Dollars on AMD Gear, Buy Stock
Hosts
- Paul Sweeney
- Scarlet Fu
Overview
This episode discusses key developments in technology, media, and pharmaceuticals, with specific focus on Meta's investment in AMD technology, potential mergers and acquisitions in media, Novo Nordisk's price adjustments for its diabetes drugs, and Home Depot's recent earnings report.
---
Key Discussions
- Meta's Investment in AMD
- Details:
- Meta Platforms plans to invest a significant amount (double-digit billions per gigawatt) in AMD's data center gear over the next five years. This partnership is aimed at enhancing its AI models.
- Meta is scheduled to start deploying this technology in the second half of 2026.
- As part of the deal, Meta will receive warrants to purchase 160 million shares of AMD.
- Insights:
- The scale of the investment is substantial, with a commitment to six gigawatts of capacity, equivalent to the output of six nuclear reactors.
- The technology focuses on AI accelerators and their performance in inference tasks.
- Meta is diversifying its partnerships, having recently announced a collaboration with NVIDIA as well.
- Warner Bros. Discovery and Paramount Skydance
- Discussion:
- Geetha Ranganathan, a Bloomberg Intelligence Analyst, provided insight into Warner Bros. Discovery's ongoing negotiations with Paramount Skydance for a potential acquisition.
- Paramount has made a bid that exceeds $30 per share, but details remain vague.
- Market Reaction:
- Netflix shareholders perceive the acquisition as a distraction rather than a necessity. Despite having robust fundamentals and new offerings, there is concern over the associated risks of M&A activities.
- Paramount's Position:
- Paramount Skydance urgently requires this deal to bolster its business as it faces challenges in growing organically, especially in a declining linear TV market.
- Novo Nordisk's Pricing Strategy
- Analysis:
- Michael Shah, a senior Pharma-Biotech analyst, discussed Novo Nordisk's decision to cut U.S. list prices for its drugs, Wegovy and Ozempic, by about 50%.
- This strategy aims to improve market access, especially for patients with high deductibles.
- Market Dynamics:
- The discount will not directly reflect in net prices but allows for better negotiation leverage with insurers.
- The competition in obesity drugs is heating up with new entrants, and the introduction of oral dosage forms could broaden patient access.
- Home Depot Earnings Report
- Performance:
- Home Depot reported better-than-expected earnings, with a notable resilience in customer demand despite macroeconomic challenges.
- The stock price rose by 2.9% following the earnings announcement.
- Market Conditions:
- The ongoing housing market remains unstable with existing home sales at a significant low, which affects consumer confidence.
- Home Depot has largely mitigated tariff impacts through diversified sourcing, but consumer sentiment remains cautious.
---
Key Takeaways
- Technology Sector: Meta's substantial investment in AMD signals a strategic push towards AI, reflecting the growing significance of AI capabilities in tech infrastructure.
- Media M&A Landscape: The negotiations between Warner Bros. Discovery and Paramount highlight the competitive nature of the media industry and the strategic necessity for companies to consolidate.
- Pharmaceutical Pricing: Novo Nordisk's pricing strategy indicates a shift towards enhancing accessibility in the competitive market for obesity drugs, with significant implications for patient affordability.
- Retail Insights: Home Depot's performance illustrates the persistent challenges in the retail sector and the importance of consumer confidence and economic conditions on sales.
---
Conclusion This episode of Bloomberg Intelligence provides a comprehensive overview of critical developments across technology, media, pharmaceuticals, and retail sectors, emphasizing strategic investments, market dynamics, and the ongoing challenges faced by companies in various industries.
Written by AI. May contain mistakes. Listen to the episode to check what was said.
Chapters
Tap a time to open that second in VOMeta's Major Deal with AMD
1:21 to 2:15
Discussion on Meta's agreement to acquire AMD chips for AI systems.
“And I receive warrants to buy 160 million AMD shares.”
Understanding Power and Data Centers
2:15 to 4:30
Analysis of the power requirements for Meta's data center plans.
“Six gigawatts of capacity is equivalent to the output of six nuclear reactors.”
Meta's Future Energy Plans
4:30 to 5:36
Exploration of Meta's long-term energy infrastructure strategies.
“Basically, like data is transferred via electrons.”
Warner Brothers Discovery Sale Insights
6:20 to 8:13
Details about the ongoing sale of Warner Brothers Discovery and its implications.
“All investing is subject to risk, Vanguard Marketing Corporation Distributor.”
Netflix's Strategic Positioning
8:13 to 12:11
Examination of Netflix's interest in acquiring Warner Brothers Discovery.
“Somebody is following this stuff very closely.”
Impact of Price Cuts on Drug Accessibility
14:01 to 17:42
Discover how price cuts on drugs can influence patient access and treatment choices.
“I think in terms of the price cut, say 50 % on the list, so it's bringing down the monthly cost down from$13.50 to about$6.75 per month.”
Future of Obesity Treatments: Oral vs. Injectable
17:42 to 19:08
Explore the potential of oral and injectable obesity treatments and what innovations lie ahead.
“We don't need to see more than 20 % weight loss.”
Home Depot Earnings and Market Outlook
20:14 to 24:24
Gain insights into Home Depot's earnings report and the current housing market conditions.
“You're listening to the Bloomberg Intelligence Podcast.”
Transcript
Automatic transcript. May contain errors.0:00Paul Sweeney:Donald Trump is rewriting the Washington rulebook and reshaping the global economy. If you're trying to connect the dots behind the headlines, Bloomberg's Trumponomics podcast is here to help. I'm Stephanie Flanders, Head of Government and Economics at Bloomberg. Every week I'll bring you a smart, focused conversation with reporters and experts from Washington, Wall Street and beyond. Listen to new episodes every Wednesday and follow Trumponomics wherever you listen. Today's show is brought to you by Vanguard. To all the financial advisors listening, let's talk bonds for a minute. Capturing value and fixed income is not easy.
0:38Paul Sweeney:Bond markets are massive, murky, and let's be real, lots of firms throw a couple flashy funds your way and call it a day. But not Vanguard. At Vanguard, institutional quality isn't a tagline. It's a commitment to your clients. We're talking top-grade products across the board of over 80 bond funds, actively managed by a 200-person global squad of sector specialists, analysts, and traders. These folks live and breathe fixed income. So if you're looking to give your clients consistent results year in and year out, go see the record for yourself at vanguard.com slash audio. That's vanguard.com slash audio.
1:14Paul Sweeney:All investing is subject to risk, Vanguard Marketing Corporation Distributor.
1:20Scarlet Fu:Bloomberg Audio Studios. Podcasts, radio, news. you're listening to the bloomberg intelligence podcast catch us live weekdays at 10 a.m eastern on apple carplay and android auto with the bloomberg business app listen on demand wherever you get your podcasts or watch us live on youtube another big big uh noise uh um i would say news
1:46Geetha Ranganathan:story coming out of the technology space meta will buy amd chips and computers designed to run artificial intelligence models over a five-year stretch beginning in the second half of 2026. And this is a kicker for me. And I receive warrants to buy 160 million AMD shares. Pretty cool. Let's get the latest reporting there. Ed Ludlow, a BTEC co-host. He's out there in San Francisco. Ed, another big deal, another two mega companies here doing some big business together. What do you make of it?
2:15Paul Sweeney:Yeah, I mean, it's very large scale. Six gigawatts of capacity is equivalent to the output of six nuclear reactors. It's enough power for several million homes. The average size of a data center is about 300 to 500 megawatts. So it is a sort of multi-year massive commitment. And the market has faded a little bit in terms of AMD share reaction. But it's quite a big bet by Meta that AMD's technology, in particular its AI accelerators, the chips that will be used to run models and what we call inference are effective. But the warrants bit, I agree, very interesting. Like, is it or is it not circular financing?
2:55Paul Sweeney:I'm always up to debate it.
2:57Scarlet Fu:And of course, we know that Meta announced a tie-up with NVIDIA just last week. So this is about Meta also diversifying its partners in this build-out. How much do we know or can we guess that Meta is spending on this partnership, on this transaction?
3:16Paul Sweeney:Well, on this AMD one, the way that Lisa Su and AMD put it is that it's double digit billions per gigawatt. So it's tens of billions of dollars over the five years. Remember, AMD is a distant number two player with respect. You know, it's all of its revenues are about 10 billion dollars a quarter, which includes the data center part. NVIDIA's just data center part is more than 50 billion dollars. So, you know, they've got some ways to catch up. But yeah, it's very significant scale. And on the Meta side, Mark Zuckerberg said it next to the president. He's committing to spending about$600 billion over the next five years or more.
3:56Paul Sweeney:And he's always said that if they misspend, quote,$200 billion here or there, the risk of not spending that money is greater for them. So the stock's down half a percentage point right now. But yeah, most people, this is consistent with what we'd expect from Meta.
4:13Geetha Ranganathan:Ed, what I'm seeing as I'm coming up to speed in all things AI and the lingo that's used in that industry, when Meta agrees to buy AMD chips, computers, okay, I get that. Where does the whole concept of measuring this in terms of gigawatts and power, how does that work into the story?
4:30Paul Sweeney:Oh, that's a really smart question. Basically, like data is transferred via electrons. There's work in more nascent fields of transferring data via photons, light in other words. But inside the server, that's how data passes through electrons. There is a heavy electricity draw to power the whole system, not just to run the GPUs and run the computations, but also everything involved in cooling and heat dissipation. We're talking about electricity, and that's why it's measured such. And to go back to Scarlett's earlier question, this is six gigawatts just between META and AMD. But Meta has plans to install like tens of gigawatts by the end of this decade.
5:11Paul Sweeney:And then beyond that, like hundreds of gigawatts, you know, completely different scale to what we've we've been talking about. That's why we track so closely in parallel what is happening with grid and energy infrastructure, because the burden is, you know, it's not you can't even compute it with the human brain. That's kind of what we're talking about. Stay with us. More from Bloomberg Intelligence coming up after this. Today's show is brought to you by Vanguard. To all the financial advisors listening, let's talk bonds for a minute. Capturing value and fixed income is not easy. Bond markets are massive, murky, and let's be real.
5:47Paul Sweeney:Lots of firms throw a couple flashy funds your way and call it a day. But not Vanguard. At Vanguard, institutional quality isn't a tagline. It's a commitment to your clients. We're talking top-grade products across the board of over 80 bond funds, actively managed by a 200-person global squad of sector specialists, analysts, and traders. These folks live and breathe fixed income. So if you're looking to give your clients consistent results year in and year out, go see the record for yourself at vanguard.com slash audio. That's vanguard.com slash audio. All investing is subject to risk, Vanguard Marketing Corporation Distributor.
6:24Paul Sweeney:The news doesn't stop on the weekends.
6:27Scarlet Fu:Context changes constantly. And now Bloomberg is the place to stay on top of it all.
6:32Paul Sweeney:Hi, I'm David Gurra. Join us every Saturday and Sunday for the new Bloomberg This Weekend.
6:37Scarlet Fu:I'm Christina Ruffini. We'll bring you the latest headlines, in-depth analysis, and big interviews. All the stories that hit home on your days off. And I'm Lisa Matteo. Watch and listen to Bloomberg This Weekend for thoughtful, enlightening conversations about business, lifestyle, people, and culture.
6:52Paul Sweeney:On Saturday mornings, we put the past week's events into context, examining what happened in the markets and the world.
6:59Scarlet Fu:Then on Sundays, we speak with journalists, columnists, and key political figures to prepare you for the week ahead. Join us as soon as you wake up and bring us with you wherever your weekend plans take you.
7:09Paul Sweeney:Watch us on Bloomberg Television, listen on Bloomberg Radio, stream the show live on the Bloomberg Business app, or listen to the podcast.
7:16Scarlet Fu:That's Bloomberg this weekend, Saturdays and Sundays starting at 7 a.m. Eastern on February 28th. Make us part of your weekend routine on Bloomberg Television, radio, and wherever you get your podcasts.
7:32Scarlet Fu:you're listening to the bloomberg intelligence podcast catch us live weekdays at 10 a.m eastern on apple carplay and android auto with the bloomberg business app listen on demand wherever you get your podcasts or watch us live on youtube one of the things we're keeping an eye on is this
7:49Geetha Ranganathan:big m &a trade in the media space warner brothers discovery all right what do we know we know that it's for sale. We know that Netflix has an offer that's been accepted by Warner Brothers Discovery. That's a good thing. But we also know that Paramount Skydance is very interested and has made repeated bids for this company. And it's been reported most recently that Paramount's actually raised its bid a little bit. But I don't know where we are. That's kind of it's been hanging on for such a long time here. Somebody is following this stuff very closely. And that's Geeta Ranganathan. She is the media analyst for Bloomberg Intelligence.
8:21Geetha Ranganathan:She follows all of the media companies out there. Geetha, I guess Paramount's coming up with a higher offer. Do we have any details of what this new offer for Warner Brothers Discovery is?
8:32Paul Sweeney:Yeah, thanks, Paul. So we don't have the dollar amount. We know that it's above$30 a share. That's the tender offer that they launched a few months ago for all of Warner Brothers Discovery. They had informally agreed to take the number up to$31 or above$31. But we still do not have clarity on the number that they have revised it to. And, you know, we're still kind of, I think, at least the Warner Brothers shareholders, Warner Brothers Discovery shareholders are still kind of waiting for that best and final offer. So still, you know, a lot of details not really disclosed. We have to wait to hear back and see what the Warner Brothers Discovery Board decides.
9:15Geetha Ranganathan:You know, I'm looking at Netflix's stock. It's down 17 percent this year. It's down 22 percent on the trail in 12 months. This is a stock that did nothing but go up for years and years. Do Netflix shareholders, how are they viewing this potential deal for Warner Brothers? Yeah.
9:31Paul Sweeney:So, you know, at this point, I think majority of the investors really view it as a distraction, at least in the near term. I mean, we've seen this happen time and time again when, you know, winning an M &A, there's always this this kind of cloud with M &A. You know, You just don't know whether the deal is actually going to work. Execution risk is there. Integration risk is there. For Netflix, there is the added complexity of a long regulatory road. One doesn't really know how any of that scrutiny is going to play out on the regulatory side, on the antitrust side. So there's just a lot of uncertainty at this time, Paul.
10:07Paul Sweeney:And we do know that the underlying story, the underlying business economics for Netflix is working. I mean, they have subscriber growth. They have pricing power. They have a new lever in the form of advertising, which is expected to take off in a big way this year. So all of the underlying drivers are in place. Does the Warner Brothers deal help? Absolutely. It is a nice to have, but it is not a must have. And I think what the Netflix shareholders have been really afraid of is Netflix overpaying for this asset. We know that at the current offer, they're already paying 25 times EBITDA. Is Warner Brothers worth that?
10:46Paul Sweeney:One can argue that, yes, it is. It does have some global, great franchises. But going above and trying to match Paramount's offer, that could be a risky move. And I don't think shareholders would like that.
10:58Geetha Ranganathan:Keitha, you know, in my view, at least, and I've read across some Wall Street research, this deal for Netflix, it's nice to have. Obviously, it's great, great assets. But for Paramount, it's kind of a must-have. What happens to Paramount Skydance if they don't get this Warner Brothers deal?
11:14Paul Sweeney:Yeah, that's the big head scratcher, Paul. I mean, there is effectively no plan B for Paramount Skydance. One of the things that has been kind of debated a lot is who can they combine with? Obviously, organically, the growth prospects look extremely bleak. They have about 60 % exposure to a declining linear TV ecosystem. The studio business, well, it's up and down. The streaming business, yeah, they've done okay. But again, it's still subscale with only about 80 million subscribers. So they absolutely need to have a dance partner. The question is, who do they combine with? If they don't have Warner Brothers Discovery, obviously, one of the choices out there is Comcast and BC.
11:55Paul Sweeney:We'll have to wait and watch because, again, there could be potentially a lot of regulatory issues because you do have two broadcast networks with CBS as well as NBC. So I'm not sure how that works, but that is potentially an option that they can explore if the Warner Brothers deal doesn't work out.
12:12Geetha Ranganathan:Stay with us. More from Bloomberg Intelligence coming up after this.
12:17Paul Sweeney:Hello, I'm Stephen Carroll. I'm in Brussels, where many of Europe's biggest decisions get made. And I'm Caroline Hepker in London. We're the hosts of the Bloomberg Daybreak Europe podcast. We're up early every weekday keeping an eye on what's happening across Europe and around the world. We do it early so the news is fresh, not recycled, and so you know what actually matters as the day gets going. From Brussels, I'm following the politics, policy and the people shaping the European Union right now. And from London, I'm looking at what all that means for markets, money and the wider economy. We've got reporters across Europe and around the globe feeding in as stories break.
12:54Paul Sweeney:So whether it's geopolitics, energy, tech or markets, you're hearing it while it happens. It's smart, calm and to the point. And it fits into your morning. You can find new episodes of the Bloomberg Daybreak Europe podcast by 7am in Dublin or 8am in Brussels, Berlin and Paris. On Apple, Spotify, YouTube or wherever you get your podcasts.
13:19Scarlet Fu:You're listening to the Bloomberg Intelligence Podcast. Catch us live weekdays at 10 a.m. Eastern on Apple CarPlay and Android Auto with the Bloomberg Business app. Listen on demand wherever you get your podcasts or watch us live on YouTube.
13:34Geetha Ranganathan:Novo Nordisk plans to slash U.S. list prices for its medicines, Wegovi and Ozempic next year. We are a Wegovi household, so this is good news there. Michael Shaw, senior pharma biotech analyst for Bloomberg Intelligence, joins us from London. Mikey, what's Novo doing here? Are they going for market share? What's the plan here?
13:56Ed Ludlow:Yeah, I think that, I mean, the slashing of the list price would, I mean, would essentially improve access. I think in terms of the price cut, say 50 % on the list, so it's bringing down the monthly cost down from$13.50 to about$6.75 per month. I mean, you won't see that sort of discount translate to the net price. So I think it's important to kind of make that distinction between the list and the net. I mean, what it does mean is, you know, NOVA will be essentially negotiating with insurers off a lower base. And then you'll probably see some adjustment in the discount or rebate offered. But I don't think that 50 percent is going to translate down to the net price.
14:40Ed Ludlow:I think what's also important to note is, I mean, it's going to benefit, you know, patients here with high deductibles, insurance plans. or patients that have coinsurance plans where they're paying a percentage of the list price. But it doesn't affect kind of pricing in the direct patient channel or the self-pay prices, which are obviously a key driver of sales and volume at the moment. So the floor here is effectively sent by Trump Rx, where the drugs are available at about$350 per month.
Read the full transcript
15:16Scarlet Fu:How do patients decide whether they want the Eli Lilly pill versus the Novo pill? Is it just whatever their doctor prescribes them or are people going out in and actively saying, I want this one over that one?
15:30Ed Ludlow:Well, the Lilly pill hasn't been. Or injection at this point.
15:34Scarlet Fu:Yeah.
15:34Ed Ludlow:But, I mean, in terms of the injectable, so ZetBound versus Wagovi, I think in general, you know, based on the prescribers that we've spoken to and also based on the clinical data that's out there, Lily's got the superior product. I think that was, you know, clear in head-to-head studies. There's a redefined four trial that read out, you know, a couple of days ago. And, you know, the base case there was for Novo's Wagovi to show non-inferiority versus ZetBound. didn't meet its primary endpoint. The weight loss actually looked inferior. There are a few caveats there. So in general, I think doctors, or the ones we've spoken to, prefer ZetBound.
16:17Ed Ludlow:In reality, it comes down to essentially cost and whatever the patient can access, either through what they can afford or their insurance plan.
16:26Geetha Ranganathan:Mike, I know you guys, since the beginning of all this, have kind of scoped out the size of the market here and the numbers are just huge. What does the introduction of an oral dosage mean for maybe growing the number of patients that may be attracted here?
16:45Ed Ludlow:Yeah, so I mean, we still see, you know, a place for orals and injectables. Orals obviously helps improve access. They're cheaper. they don't face the same fill and finish constraints of an injectable treatment and then in terms of kind of positioning whether they're going to use for you know weight loss induction or weight loss maintenance I think that you know the jury's still out on that you know different people we've spoken to and different companies that we've spoken to you know have different views on the positioning of an oral versus an injectable but I mean I think there's going to be room for both.
17:22Ed Ludlow:And, you know, both formulations are going to be utilized. What's the next real, I guess, big move here in this part of the market?
17:34Geetha Ranganathan:I mean, I think getting the oral dosage is big. What's the next big thing? Is it just improving it, maybe lowering the side effects? What are you looking for next?
17:44Ed Ludlow:um yes i mean when we look at hey we've done our analysis into the pipeline um for obesity um so i mean there's you know more than 190 assets in clinic it's heavily dominated by by glp1 um so there's going to be a need for new mechanisms outside of glp1 um one of the key ones coming through the pipeline at the moment and it's going to be in focus this year um is going to be amelin um so the idea here is to to have um i mean it's a different it's a non-incredited mechanism um it's an injection a weekly injection um but the idea here is to basically have glp1 like weight loss um but with with better tolerability so as you know you know one of the main drawbacks at the moment of glp1 therapy is the gi side effects the gastrointestinal side effects which leads to discontinuations.
18:37Ed Ludlow:So amlin aims to solve that problem. We don't need to see more than 20 % weight loss. So amlin drugs are generally targeting 15 % to 20 % weight loss over a year. But we do want to see that improvement in tolerability. If it can show improvements in body composition, so that's fat mass loss versus muscle mass loss, that's going to be considered a bonus. So that's really going to be, you know, the next focus or the next wave of innovation in BC. Stay with us.
19:09Geetha Ranganathan:More from Bloomberg Intelligence coming up after this.
19:13Paul Sweeney:This is Tom Keen inviting you to join us for the Bloomberg Surveillance Podcast. It's about making you smarter every business day.
19:22Geetha Ranganathan:I'm Paul Sweeney. We bring you complete coverage of the U.S. market open. We cover stocks, bonds, commodities, even crypto, all the information you need to excel.
19:30Paul Sweeney:And I'm Alexis Christophorus. Bloomberg Surveillance also brings you the analysis behind the headlines. We do that through conversations with the smartest names in economics, finance, investment, and international relations. We do all this live each and every weekday that bring you the best analysis in our daily podcast. Search for Bloomberg Surveillance on Apple, Spotify, YouTube, or anywhere else you listen.
19:54Geetha Ranganathan:On the East Coast, listen at lunch. And on the West Coast, listen as soon as you wake up.
19:58Paul Sweeney:That's the Bloomberg Surveillance Podcast with Tom Keen, Paul Sweeney, and me, Alexis Christophorus. Subscribe today wherever you get your podcasts. Bloomberg Surveillance, essential listening each and every business day.
20:14Scarlet Fu:You're listening to the Bloomberg Intelligence Podcast. Catch us live weekdays at 10 a.m. Eastern on Apple CarPlay and Android Auto with the Bloomberg Business App. Listen on demand wherever you get your podcasts or watch us live on YouTube.
20:29Geetha Ranganathan:Earnings still kind of have trickling in here. We had Home Depot reported some numbers today. Some pretty good numbers, pretty good outlook. Stock's up about 2.9 % today. It's up about 13 % year to date. It's got a market cap of$386 billion. Let's check in with Drew Redding. He covers all the home builders and all the related stocks there, including the Home Depots of the world. Drew, what'd you make from the earnings coming out of Home Depot?
20:55Scarlet Fu:Yeah, it was a solid print for Home Depot, beat on same-store sales with a little bit of weather impact. I think, importantly, they maintained their four-year guidance that they issued at their December analyst day calling for comp sales of 0 % to 2%. You know, quite frankly, when you think about Home Depot, it's really been steady as she goes for several quarters. If you strip out all the weather impacts that we've seen over the last couple of years, they're really growing demand at about a 1 % comp range. So their customer has been resilient. As you heard on the call, though, the problem is there's just not really a catalyst for a significant next leg of growth.
21:32Scarlet Fu:And a lot of that has to do with what we're seeing in the housing market. Right. Affordability still remains a big issue, although mortgage rates have come down. So that should be a positive for Home Depot, no? Yeah, of course. Lower mortgage rates, we do expect, will stimulate demand throughout the year. It should also encourage more refinancing activity, which could support bigger ticket spending. The issue is we just haven't seen it yet. If you look at existing home sales in December, they were below a$4 million annualized rate. That's about 25 % below what a normalized market would look like.
22:09Scarlet Fu:One of the big issues that's out there, we heard it from Home Depot and we hear it from all of the builders that we talked to is that there's just a lack of confidence at the moment, whether it's the direction of the economy or the outlook for employment. There's just a lack of urgency among buyers. And if you think about it, there's a lot of people sitting on the fence, looking at the headlines, saying to themselves, look, maybe home prices are going to come down, maybe mortgage rates are going to come down further. So they're taking more of a wait and see approach. So I think until we could kind of rebuild that confidence, lower rates aren't having much of an impact.
22:42Geetha Ranganathan:Drew, just in the last several days, the tariffs story and narrative has kind of reared its ugly head again. Just to refresh our memory, how did the Home Depots of the world, how they dealt with tariffs over the last year or so? Sure.
22:59Scarlet Fu:So for some context, Home Depot sources about 50 % to 60 % of the products they sell from North America. So those aren't subject to tariffs. The remaining portion comes from a number of countries. They've done well to diversify their supply chain. What they told us today is that they've pretty much implemented all of the pricing in terms of tariffs that they're going to do. It's about a 3 % increase. We've seen it in average ticket this quarter, and they expect that to drive average ticket in 2026. As it relates to the comments we heard Friday and over the weekend, as you would expect, given it's happening in real time in a fluid situation.
23:41Scarlet Fu:They said they're still analyzing the impact. And very quickly, Drew, before we let you go, Home Depot's small arrival Lowe's will be reporting earnings tomorrow morning. Are we expecting a similar story from Lowe's? Yeah, I would expect to hear from Lowe's the strength of their professional customer. They've done well to invest in a space where they've kind of ignored for a couple of years. That's really driven the outperformance of Home Depot. So we expect to hear relative strength there, a little pickup from weather. But big picture, I do expect to continue to hear that big ticket discretionary spending remains challenged by those same things that we discussed, whether it's related to housing or overall sentiment from the consumer.
24:23Scarlet Fu:This is the Bloomberg Intelligence Podcast, available on Apple, Spotify and anywhere else you get your podcasts. Listen live each weekday, 10 a.m. to noon Eastern on Bloomberg.com, the iHeartRadio app, TuneIn, and the Bloomberg Business app. You can also watch us live every weekday on YouTube and always on the Bloomberg Terminal.
24:50Paul Sweeney:I'm Barry Ritholtz, inviting you to join me for the Masters in Business podcast. Every week, we bring you fascinating conversations with the people who shape markets, investing, and business. CEOs, fund managers, billionaires, Nobel laureates, traders, analysts, economists, everybody that affects what's going on in the market. Whether you own stocks, bonds, real estate, commodities, crypto, you really need to hear these conversations. Sometimes it's behaviorists like Dick Thaler or Bob Schiller. Sometimes it's fund managers like Peter Lynch, Bill Miller, Ray Dalio. Sometimes it's authors, Michael Lewis, author of The Big Short, and Moneyball.
25:35Paul Sweeney:Regardless of the conversation, these are the folks that move markets each week. That's the Masters in Business podcast with me, Barry Ritholtz. Listen on Apple, Spotify, or wherever you get your podcasts.
From the publisher
Watch Scarlet and Paul LIVE every day on YouTube: http://bit.ly/3vTiACF.
Market news and in-depth company research.
Bloomberg Intelligence hosted by Paul Sweeney and Scarlet Fu
-Ed Ludlow, BTech Co-Anchor, discusses news that Meta Platforms will deploy data center gear based on processors from Advanced Micro Devices in a deal worth “double-digit billions” of dollars per gigawatt. Meta will buy AMD chips and computers designed to run artificial intelligence models over a five-year stretch.
-Geetha Ranganathan, Bloomberg Intelligence Analyst on US Media, discusses Warner Bros. Discovery considering a new takeover bid from Paramount Skydance Corp., with its board set to review the proposal and respond.
-Michael Shah, Bloomberg Intelligence Senior Pharma-Biotech Analyst, discusses Novo Nordisk plans to slash the US list prices for its blockbusters Wegovy and Ozempic next year as the drugmaker struggles to claw back a larger share of the obesity market.
-Drew Reading, Bloomberg Intelligence U.S Homebuilding Analyst, discusses Home Depot earnings. Home Depot reported a key sales metric that beat expectations in the latest quarter on steady demand, though the retailer cautioned that macroeconomic challenges remain.
See omnystudio.com/listener for privacy information.
